Trametiglue
Trametiglue, a derivative of Trametinib (HY-10999), targets both KSR-MEK and RAF-MEK with unprecedented potency and selectivity via unique interfacial binding interactions[1].
Product Specifications
CAS Number
[2666940-97-0]
UNSPSC
12352005
Target
MEK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/trametiglue.html
Purity
98.81
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C2=C(N(C)C(C(C)=C2N(C3=CC(NS(=O)(NC)=O)=CC=C3)C(N1C4CC4)=O)=O)NC5=CC=C(C=C5F)I
Molecular Formula
C25H24FIN6O5S
Molecular Weight
666.46
References & Citations
[1]Khan ZM, et al. Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature. 2020 Dec;588 (7838) :509-514.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MEK1; MEK2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MIEN1 (Migration and Invasion Enhancer 1, HBV X-transactivated Gene 4 Protein, HBV XAg-transactivated Protein 4, Protein C35, C17orf37, RDX12, XTP4, MGC14832)
MIEN1 (Migration and Invasion Enhancer 1, HBV X-transactivated Gene 4 Protein, HBV XAg-transactivated Protein 4, Protein C35, C17orf37, RDX12, XTP4, MGC14832)